The three genomics players all announced preliminary results prior to speaking, and all had more news to add about their recent success and their plans to grow the demand for cancer diagnostics.

Exact Sciences’ next generation of Cologuard, which could be on the market later this year, clearly outperforms its previous.

Each month, Start-Up presents a survey of technology transfer deals--licensing agreements between companies and universities or other research institutions--in the fields of life sciences, including pharmaceuticals, medical devices, in vitro diagnostics and research/analytical instrumentation and reagents.